Xbrane Biopharma releases interim report for Q1
DATUM: 2017-05-18
KATEGORI:
Private Equity
Xbrane Biopharma ABs interim report for the period January – March 2017 is now available on the Company’s website, www.xbrane.com
Period January – March:
- Net sales SEK 6,840 thousand (854)
- Total income SEK 6,980 thousand (861)
- Earnings before tax SEK -10,134 thousand (-5,530)
- Cash flow from current operations SEK -9,353 thousand (-7,556)
- Earnings per share before dilution SEK -2.19 (-2.48)
